Mitral Valve Regurgitation Quantification From 3D Color Doppler Ultrasound - Standard of Care Data Collection

NCT ID: NCT03286088

Last Updated: 2021-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-22

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study primarily aims to collect standard of care clinical data in a wide spectrum of simple to complex mitral valve regurgitation (MVR) cases to validate a post-processing stand-alone software prototype (QFlow), developed by Philips Research Paris (Medisys).

Investigator does not intervene in the care of the patient, but simply collects standard of care images and measurements that are needed for the validation of the investigational software.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve Regurgitation of Any Grade

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

TransEsophageal Echocardiography + TransThoracic Echocardiography

Group Type OTHER

TransEsophageal Echocardiography and TransEsophageal Echocardiography

Intervention Type DIAGNOSTIC_TEST

imaging as standard practice

Group B

TransEsophageal Echocardiography + TransThoracic Echocardiography + cardiac Magnetic Resonance

Group Type OTHER

TransEsophageal Echocardiography and TransEsophageal Echocardiography

Intervention Type DIAGNOSTIC_TEST

imaging as standard practice

Cardiac Magnetics Resonance

Intervention Type DIAGNOSTIC_TEST

imaging as standard practice

Group C

TransEsophageal Echocardiography + TransThoracic Echocardiography + MitraClip

Group Type OTHER

TransEsophageal Echocardiography and TransEsophageal Echocardiography

Intervention Type DIAGNOSTIC_TEST

imaging as standard practice

MitraClip

Intervention Type DIAGNOSTIC_TEST

imaging as standard practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TransEsophageal Echocardiography and TransEsophageal Echocardiography

imaging as standard practice

Intervention Type DIAGNOSTIC_TEST

Cardiac Magnetics Resonance

imaging as standard practice

Intervention Type DIAGNOSTIC_TEST

MitraClip

imaging as standard practice

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* both genders
* age between 18 and 85 years old (adult, senior)
* sinus rhythm
* hHemodynamic stable
* mitral valve regurgitation (MVR) of any grade i.e., from mild to severe as determined by assessment of a qualifying TransThoracic Echocardiography (TTE) exam at Saint-Luc University Hospital
* scheduled for TransEsophageal Echocardiography (TEE) at Saint-Luc University Hospital, as part of the subject's routine standard of care
* subjects has functional capacity to give written informed consent

* a second sub-group (B) of 50 subjects with additional inclusion criterion: scheduled for cardiac Magnetic Resonance (cMR), as part of the subject's routine standard of care
* a third sub-group (C) of 20 subjects with additional inclusion criterion: scheduled for MitraClip transcatheter mitral valve repair (MitraClip) procedure as part of the subject's routine standard of care

Exclusion Criteria

* pregnancy
* subject lacks functional capacity to give written informed consent belongs to a vulnerable population per investigator's judgment or subject has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures

Among the120 subjects, there will be three (3) sub-groups as follows:
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philips Electronics Nederland B.V. acting through Philips CTO organization

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saint Luc University Hospital

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ICBE-2-15217

Identifier Type: -

Identifier Source: org_study_id